FORT LAUDERDALE, Fla., Nov. 5 /PRNewswire-FirstCall/ Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer in laser optical breast cancer imaging systems, announced that CT Laser Mammography (CTLM(R)) results were exhibited at the 4th Congress of the World Society for Breast Health in Tianjin, China, October 18th - 21st.
The Congress attracted more than 500 breast health experts from 23 different countries and offered 29 clinical and academic presentations on breast health, including epidemiology, screening, diagnosis, prevention, and the treatment of breast cancer.
IMDS local representatives exhibited clinical imaging cases from international sites. Several meeting attendees visited the recent CTLM installation at the Tianjin Medical University Cancer Institute and Hospital, where clinical studies are now underway.
Explained Tim Hansen, IMDS Chief Executive Officer: "Exhibiting at the Congress allowed us to support our global commercialization efforts while highlighting the research that is being conducted at the Tianjin Medical University Cancer Institute and Hospital as well as at Beijing Friendship Hospital. Having an operating CTLM system in the same city helped reinforce our messages to those seriously considering our approach. China represents a significant market; CTLM solves real clinical problems for these users and their patients."
The Congress was organized by the World Society for Breast Health, the Chinese Oncology Society and the Chinese Medical Association, along with the Tianjin Medical University Cancer Institute and Hospital, which served as the local organizer. Previous World Society for Breast Health Congresses have been held in Istanbul, Turkey; Budapest, Hungary; and Tokyo, Japan.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM(R) system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM(R)) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
For more information, visit our website: http://www.imds.com.
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
|SOURCE Imaging Diagnostic Systems, Inc.|
Copyright©2007 PR Newswire.
All rights reserved